RxDoctor Payments Data

Karen McGarry

Physician Assistant · Schenectady, NYNPI 1578679338

Payments from drug & device makers

$2,483in general payments, 2019–2025

Across 105 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$576
  • GSK$553
  • Novo Nordisk$338
  • AstraZeneca$196
  • Atos Medical Inc$125
  • Esperion Therapeutics, Inc.$119
  • plus $576 from 18 others

What the payments were for

  • Food & beverage$2,483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,483 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$55,909
Medicare patients
258
Services billed
1,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$17,528
FarxigaDapagliflozin Propanediol18$16,680
EliquisApixaban14$11,435
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,286
PaxlovidNirmatrelvir/Ritonavir12$1,347
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,236
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav89$1,079
Cefdinir52$1,060
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,032
Albuterol Sulfate HfaAlbuterol Sulfate31$1,025
CefuroximeCefuroxime Axetil39$882
Omeprazole57$819
Rosuvastatin Calcium48$807
Atorvastatin Calcium72$798
Losartan Potassium32$627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$338$17,52813 claims
AstraZenecaFarxiga$196$16,68018 claims
PfizerEliquis, Paxlovid$18$12,78326 claims
GSKAnoro Ellipta$553$7,28616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →